Merck & Co's new combo asthma drug expected to garner peak year sales of over $250 million
Following its expected launch this year for the treatment of asthma, US drug major Merck & Co's formoterol/mometasone combination will garner peak year sales of more than $250 million in the USA, France, Germany, Italy, Spain and the UK, according to a new report from Decision Resources.
The Pharmacor 2010 finding from the topic titled Asthma reveals that formoterol/mometasone, a twice-daily long acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination, will launch in 2010 in the USA and in Europe as a maintenance treatment for asthma in patients aged 12 years or older.
SkyePharma drug delayed
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze